Literature DB >> 3491910

Clinical, immunologic, and serologic findings in men at risk for acquired immunodeficiency syndrome. The San Francisco Men's Health Study.

W Lang, R E Anderson, H Perkins, R M Grant, D Lyman, W Winkelstein, R Royce, J A Levy.   

Abstract

Forty-nine percent of homosexual/bisexual men were positive for antibody to the human immunodeficiency virus (HIV) in a population-based probability sample of 1034 single men recruited from San Francisco. All heterosexual men were negative. Among seropositive men, marked lymphadenopathy was present in 29%, and 16% had at least two other symptoms or signs suggestive of HIV infection. However, lymphadenopathy alone failed to indicate severity of immune impairment. The occurrence of two or more clinical signs and symptoms, except for marked lymphadenopathy, correlated with HIV infection, diminished skin test reactivity, and reduction in Leu 3a T cells. Twenty-nine percent of seropositive men had fewer than 400 absolute Leu 3a T helper cells per microliter (less than 0.4 X 10(9)/L). Seronegative homosexual/bisexual men did not differ from heterosexual men in any clinical or laboratory variables except for increased numbers of suppressor Leu 2a T suppressor cells per microliter.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3491910

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  16 in total

Review 1.  Assessing HIV infection in primary care practice.

Authors:  H J Makadon
Journal:  J Gen Intern Med       Date:  1991 Jan-Feb       Impact factor: 5.128

2.  Histories of substance use and risk behavior: precursors to HIV seroconversion in homosexual men.

Authors:  M A Chesney; D C Barrett; R Stall
Journal:  Am J Public Health       Date:  1998-01       Impact factor: 9.308

Review 3.  International travel and HIV infection.

Authors:  C F von Reyn; J M Mann; J Chin
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

4.  Behavioral characteristics and laboratory parameters in homo- and bisexual men in West Berlin: an evaluation of five years of testing and counselling on AIDS.

Authors:  S Deininger; R Müller; I Guggenmoos-Holzmann; U Laukamm-Josten; U Bienzle
Journal:  Klin Wochenschr       Date:  1990-09-14

5.  Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells.

Authors:  M Janini; M Rogers; D R Birx; F E McCutchan
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  Differences in gay men's AIDS risk knowledge and behavior patterns in high and low AIDS prevalence cities.

Authors:  J S St Lawrence; H V Hood; T Brasfield; J A Kelly
Journal:  Public Health Rep       Date:  1989 Jul-Aug       Impact factor: 2.792

7.  Functional characterization of human immunodeficiency virus type 1 nef genes in patients with divergent rates of disease progression.

Authors:  N L Michael; G Chang; L A d'Arcy; C J Tseng; D L Birx; H W Sheppard
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Dissociation of unintegrated viral DNA accumulation from single-cell lysis induced by human immunodeficiency virus type 1.

Authors:  L Bergeron; J Sodroski
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

9.  Effect of improved access to antiretroviral therapy on clinical characteristics of patients enrolled in the HIV care and treatment clinic, at Muhimbili National Hospital (MNH), Dar es Salaam, Tanzania.

Authors:  Sabina F Mugusi; Julius C Mwita; Joel M Francis; Said Aboud; Muhammad Bakari; Eric A Aris; Andrew B Swai; Ferdinand M Mugusi; Kisali Pallangyo; Eric Sandstrom
Journal:  BMC Public Health       Date:  2010-05-28       Impact factor: 3.295

10.  Maintenance of safer sexual behaviors and predictors of risky sex: the San Francisco Men's Health Study.

Authors:  M L Ekstrand; T J Coates
Journal:  Am J Public Health       Date:  1990-08       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.